HVTN 106
Status:Completed
Phase:I
Principal Investigator(s):Lindsey Baden, Brigham and Women's Hospital
Objective:The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.
Last updated March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
Mode of DeliveryIntramuscular
ARMsPlacebo Comparator
Official Code:
NCT02296541
Trial Sponsors:
CHAVI, HVTN, IPPOX, MHRP, NIAID
Start Date
End Date
December 1, 2014
July 6, 2020
Enrollment:105
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women